Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2003
12/04/2003WO2003099323A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003WO2003099309A1 Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits
12/04/2003WO2003099308A1 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng
12/04/2003WO2003099302A1 A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere
12/04/2003WO2003099292A1 Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
12/04/2003WO2003099289A2 Compositions and their uses for alleviating pain
12/04/2003WO2003099285A1 Compositions comprising hepoxilin analogs and their use in the treatment of cancer
12/04/2003WO2003099263A1 At least partially degradable films containing an active ingredient and method for the production thereof
12/04/2003WO2003099260A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection
12/04/2003WO2003099221A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003WO2003099218A2 Anti-cancer formulation
12/04/2003WO2003099211A2 Mitotic kinesin inhibitors
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099193A2 Vaccines
12/04/2003WO2003099192A2 Bis-aromatic alkanols
12/04/2003WO2003098991A2 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability
12/04/2003WO2003090818A3 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003WO2003088920A3 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics
12/04/2003WO2003086456A3 Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
12/04/2003WO2003086309A3 NF-κB INHIBITORS
12/04/2003WO2003083041A3 Cripto-specific antibodies
12/04/2003WO2003080841A8 Calcineurin activators
12/04/2003WO2003075921A3 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/04/2003WO2003072736A3 Reagents and treatment methods for autoimmune diseases
12/04/2003WO2003072062A3 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
12/04/2003WO2003069998A8 Stable compositions comprising tezacitabine
12/04/2003WO2003066810A3 Recombinant bovine immunodeficiency virus based gene transfer system
12/04/2003WO2003065787A3 Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
12/04/2003WO2003064596A3 Desaturase genes, enzymes encoded thereby, and uses thereof
12/04/2003WO2003061593A3 Novel targeted compositions for diagnostic and therapeutic use
12/04/2003WO2003059379A3 Immunogenic carcinoembryonic antigen (cea)
12/04/2003WO2003057169A3 4-dedimethylamino tetracycline compounds
12/04/2003WO2003057168A3 Cancer-associated epitope
12/04/2003WO2003053465A3 Lyophilized preparation containing antibodies to the egf receptor
12/04/2003WO2003050499A3 Use of a labeled ligand having human cd4 specificity
12/04/2003WO2003050267A3 Method of isolating extract from the euphorbaciae obesa plant and methods for using the same
12/04/2003WO2003050122A3 Mitotic kinesin inhibitors
12/04/2003WO2003048328A3 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
12/04/2003WO2003043581A3 Composition and method for modulating bar/fxr receptor activity
12/04/2003WO2003040725A3 Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen
12/04/2003WO2003039523A3 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
12/04/2003WO2003032920A3 Oligonucleotide modulation of cell adhesion
12/04/2003WO2003028736A3 Pharmaceutical preparations comprising alkyl phosphocholine compounds in liposomes which may be sterile-filtered or heat-sterilised
12/04/2003WO2003028715A3 Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
12/04/2003WO2003028642A3 Methods of inhibiting metastases
12/04/2003WO2003028537A3 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
12/04/2003WO2003027085A3 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
12/04/2003WO2003026590A3 Biological control of nanoparticles
12/04/2003WO2003021273A3 Diagnosis of carcinomas
12/04/2003WO2003020280A3 Compositions and use thereof in the treatment of cancer
12/04/2003WO2003018755A3 Wild-type ras as a cancer therapeutic agent
12/04/2003WO2003013554A3 Aromatase inhibitors from broussonetia papyrifera
12/04/2003WO2003008579A3 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
12/04/2003WO2003007987A3 Haptenizing cancer cell components for the preparation of cancer vaccines
12/04/2003WO2003006996A3 Natural ligand of gpcr chemr23 and uses thereof
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002099068A3 LCES AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/04/2003WO2002094186A3 Urazole compounds useful as anti-inflammatory agents
12/04/2003WO2002082077A3 Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes
12/04/2003WO2002074344A3 Peg-conjugates of hgt-nk4
12/04/2003WO2002074314A9 Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
12/04/2003WO2002073208A3 Anti-epileptogenic agents
12/04/2003WO2002070555A3 Method of modulating the proliferation of medullary thyroid carcinoma cells
12/04/2003WO2002068635A3 Methods of inhibiting expression of a target gene in mammalian cells
12/04/2003WO2002068397A8 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
12/04/2003WO2002058694A3 Method of treating hematologic tumors and cancers using beta lapachone
12/04/2003WO2002057427A3 Mammalian tumor susceptibility gene products and their uses
12/04/2003WO2002030462A3 Hedgehog antagonists, methods and uses related thereto
12/04/2003WO2002024947A3 Cancer associated protein kinases and their uses
12/04/2003WO2001072771A3 Insulin and igf-1 receptor agonists and antagonists
12/04/2003US20030226158 Cds1 knockout cells and mice, and their utilization
12/04/2003US20030225450 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003US20030225309 Radioactive compositions and methods of use thereof
12/04/2003US20030225277 9-(2-(2,4-cis(S)-4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphor-inan-2 -yl)methoxyethyl)adenine by coupling the dichloridate of 9-(2-phosphonyl- methoxyethyl- or propyl)adenine (PMEA)(PMPA) with a 1-(chlorophenyl) propylene-1,3-diol
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225272 Novel mmp-2/mmp-9 inhibitors
12/04/2003US20030225269 Inhibitors of interleukin-1beta converting enzyme
12/04/2003US20030225158 Compounds that modulate PPAR activity and methods for their preparation
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225150 Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225111 Use of a quinazoline derivative such as 1-(2,6-dichloro-phenyl)-3-(7-(3-morpholinopropoxy)quinazolin-4-yl) urea to produce an antiangiogenic and/or vascular permeability reducing effect
12/04/2003US20030225109 Inducing contraception, treat progesterone-related carcinomas and adenocarcinomas; hormone replacement therapy
12/04/2003US20030225106 Prophylaxis and treatment of angiogenesis mediated diseases such as cancer
12/04/2003US20030225102 Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate
12/04/2003US20030225100 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same
12/04/2003US20030225094 E.g, 4-(2-((6R,12aR)-6-benzo(1,3)dioxol-5-yl-1,4-dioxo -3,4,6,7,12,12a-hexahydro-1H-pyrazino-(1',2':1,6)pyrido(3,4-b) indol-2-yl)ethyl)-benzenesulfonamide; inhibitors of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase
12/04/2003US20030225093 Cyclic gmp-specific phosphodiesterase inhibitors
12/04/2003US20030225090 Oxindole derivatives
12/04/2003US20030225086 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
12/04/2003US20030225076 Mitogen ERK Kinase ("MEK") enzyme inhibitors
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225073 Compositions useful as inhibitors of protein kinases
12/04/2003US20030225072 Opioid receptor active compounds
12/04/2003US20030225061 Protease inhibitors
12/04/2003US20030225060 Acylated piperidine derivatives as melanocortin-4 receptor agonists
12/04/2003US20030225056 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
1 ... 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 ... 2211